Stock NVRO NEVRO CORP.
Add to a list
To use this feature you must be a member
Log inSign up

News Nevro Corp.

Equities

NVRO

US64157F1030

Delayed Nyse
Other stock markets
 04:00:01 2024-05-24 pm EDT 		5-day change 1st Jan Change
9.39 USD 0.00% Intraday chart for Nevro Corp. -17.63% -56.37%
May. 22 Citigroup Downgrades Nevro to Sell From Neutral, Adjusts Price Target to $9 From $13.50 MT
May. 14 Transcript : Nevro Corp. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
PR
Citigroup Downgrades Nevro to Sell From Neutral, Adjusts Price Target to $9 From $13.50
MT
Transcript : Nevro Corp. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM
Nevro to Present at BofA Securities 2024 Healthcare Conference
PR
Truist Securities Lowers Nevro's Price Target to $11 From $14, Hold Rating Maintained
MT
Piper Sandler Adjusts Nevro's Price Target to $12 From $15, Maintains Underweight Rating
MT
Wells Fargo Trims Nevro Price Target to $13 From $14, Maintains Equal Weight Rating
MT
Nevro Corp. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Nevro : First Quarter 2024 Earnings Presentation
PU
Transcript : Nevro Corp., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (NVRO) NEVRO Reports Q1 Revenue $87M, vs. Street Est of $97.9M
MT
Nevro: Q1 Earnings Snapshot
AQ
Nevro Reports First-Quarter 2024 Financial Results
PR
Nevro Corp. Provides Earnings Guidance for the Second Quarter Ending June 30, 2024 and Revises Earnings Guidance for the Full Year Ending December 31, 2024
CI
Nevro Corp. Announces Resignation of Richard B. Carter as Chief Accounting Officer and Principal Accounting Officer, Effective May 10, 2024
CI
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
PR
RBC Lowers Price Target on Nevro to $16 From $18, Keeps Sector Perform Rating
MT
Mizuho Adjusts Price Target on Nevro to $16 From $20, Maintains Neutral Rating
MT
Non-Opioid Revolution: Beacons of Hope in Opioid Crisis and a $50 Million Spin-Off
AQ
Citigroup Cuts Price Target on Nevro to $16 From $18, Maintains Neutral Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. NVRO Stock
  4. News Nevro Corp.